Literature DB >> 37868

Onset and duration of beta-adrenergic receptor blockade following single oral dose acebutolol hydrochloride (Sectral).

R D Watson, W A Littler.   

Abstract

1. The onset and duration of action of once daily acebutolol (400 mg) on resting and exercise heart rate and blood pressure were studied in normal subjects in a double-blind, cross-over trial against placebo. Subjects were studied 1.5, 3, 8 and 24 h after the first dose and 24 h after the fifth dose. 2. Resting and exercise heart rate and blood pressure were significantly reduced within 90 min of the first dose. 3. A significant reduction in these variables persisted throughout 24 h after the fifth daily dose. However, at 24 h the effects were considerably attenuated, the falls in resting and exercise systolic blood pressure being only 5%. 4. A linear relationship was noted between log serum drug level and percentage reduction of exercise heart rate.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 37868      PMCID: PMC1429672          DOI: 10.1111/j.1365-2125.1979.tb04642.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Problems in assessing beta-adrenoceptor antagonism in man.

Authors:  C F George
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

2.  Plasma levels and beta-adrenoceptor blockade with acebutolol, practolol and propranolol in man.

Authors:  M F Cuthbert; R F Collins
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

3.  The effect on blood pressure of beta-adrenoceptor blocking drugs administered once daily and their duration of action when therapy is ceased.

Authors:  M Wilson; G Morgan; T Morgan
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

4.  Control of heart rate by the autonomic nervous system. Studies in man on the interrelation between baroreceptor mechanisms and exercise.

Authors:  B F Robinson; S E Epstein; G D Beiser; E Braunwald
Journal:  Circ Res       Date:  1966-08       Impact factor: 17.367

Review 5.  Acute and long-term studies of the mechanisms of action of beta-blocking drugs in lowering blood pressure.

Authors:  K O Stumpe; R Kolloch; H Vetter; W Gramann; F Krück; C Ressel; M Higuchi
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

6.  Contribution of atenolol, bendrofluazide, and hydrallazine to management of severe hypertension.

Authors:  R G Wilcox; J R Mitchell
Journal:  Br Med J       Date:  1977-08-27

7.  Atenolol once-daily in hypertension.

Authors:  T A Jeffers; J Webster; J C Petrie; N P Barker
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

  7 in total
  4 in total

Review 1.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

2.  Comparison of once and twice daily administration of acebutolol in hypertension.

Authors:  R D Watson; T J Stallard; W A Littler
Journal:  Br J Clin Pharmacol       Date:  1980-02       Impact factor: 4.335

3.  Observations on the clinical pharmacology and plasma concentrations of diacetolol, the major human metabolite of acebutolol.

Authors:  K Ohashi; S J Warrington; C M Kaye; G W Houghton; M Dennis; R Templeton; P Turner
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

4.  Cardiovascular effects of single oral doses of the new beta-adrenoceptor blocking agents betaxolol (SL 75212) in healthy volunteers.

Authors:  P J Cadigan; D R London; B L Pentecost; G Bianchetti; R Gomeni; J R Kilborn; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1980-06       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.